58 results about "Viral Activity" patented technology

The invention belongs to the technical field of biological medicine, and particularly relates to application of anethomycin in preparation of medicine for inhibiting cysteine protease activity. The invention discovers that anethomycin has the function of inhibiting the activity of virus cysteine protease, especially 3C or 3CL protease, for the first time. Molecular docking proves that anethomycin can effectively bind to the catalytic activity center of Senecavirus (SVA) 3C protease. An in-vitro FRET enzyme activity experiment proves that the inhibition rate of 50 [mu] M of anethomycin on SVA 3C protease reaches up to 88.5%. Cellular level experiments show that the anethomycin can significantly inhibit replication of SVA viruses, shows broad-spectrum antiviral activity on various viruses such as encephalomyocarditis viruses (EMCV), porcine reproductive and respiratory syndrome viruses (PRRSV) and porcine deltacoronaviruses (PDCoV), and is low in cytotoxicity and high in selectivity index (SI).

The invention relates to the technical field of nitrogen heterocyclic compounds, in particular to nitrogen heterocyclic alkaloid and application thereof in preventing and treating plant viruses. The structural formula of the nitrogen heterocyclic alkaloid is shown in the specification, wherein X is selected from any one of-OCH3,-OCH2CH3 and-O (CH2) 2CH3. An antiviral activity test result shows that the azacyclo-alkaloid series compounds provided by the invention have antiviral activity, and the antiviral activity level of part of azacyclo-alkaloid reaches or even exceeds that of a positive control drug. Therefore, the azacyclo-alkaloid is expected to be applied to prevention and treatment of plant viruses.

The application discloses an indole 3-amide derivative, a preparation method and application thereof. The compound has a structure shown in general formula I. The application further relates to a pharmaceutical composition containing the compound with the structure of formula I. Activity screening experiments show that the compound has good anti-dengue virus activity, and thus the application further provides application of the compound in preparation of an anti-dengue virus drug.

The invention discloses an application of sodium oxamate in preparation of anti-influenza virus products, and provides an application of sodium oxamate as a lactic dehydrogenase A inhibitor in preparation of anti-influenza virus products, the sodium oxamate has broad-spectrum antiviral activity, and can play a unique action mechanism by regulating host cell metabolism (such as protein lactylation). And a new direction is provided for overcoming virus resistance.

The invention relates to application of a compound in preparation of a medicine for treating related diseases and / or symptoms caused by new coronavirus infection. The compound has efficient activity of inhibiting new coronavirus infection in vivo and in vitro, and is low in cytotoxicity. Meanwhile, as a host AXL receptor inhibitor, the SARS-CoV-2 inhibitor blocks the binding site of the SARS-CoV-2 and the receptor AXL of the SARS-CoV-2, and as an interferon inducer, the SARS-CoV-2 inhibitor can strongly up-regulate the expression of I-type interferon, and double-targeting host receptor and interferon pathway can exert strong anti-neocoronavirus activity. Therefore, the compound disclosed by the invention is based on a novel anti-new coronavirus double-targeting strategy of blocking AXL receptor effect and up-regulating interferon response, is relatively safe to host cells, and can be used for preventing and treating new coronavirus infection.

The invention discloses a compound as shown in a formula 1 and pharmaceutically acceptable salts thereof, and discloses a preparation method and application thereof. The compound as shown in the formula 1 in the figure 2 and the pharmaceutically acceptable salt thereof can be used for preparing antiviral drugs or drugs for treating dengue fever. The compound as shown in the formula 1 provided by the invention has good anti-dengue virus activity and low cytotoxicity, DENV1-4 can be remarkably inhibited at the concentration of 1 mu M, especially EC50 of cellular level anti-DENV-2 can reach 2.12 nM, and stronger antiviral activity is shown. In addition, the CC50 of the compound 1 is greater than 200 [mu] M, and the toxicity to host cells is lower. The compound 1 provided by the invention has higher safety and treatment window, has potential to be used for preparing anti-dengue virus drugs, and has great popularization and application values.

The invention relates to an anti-influenza compound as well as a preparation method and application thereof, and the anti-influenza compound has a structure as shown in formula (I): (I) wherein X1 is CR3 or N; x2 is CR4 or N; z is CR5 or N; y1 is CR6 or N; y2 is CR7 or N; y3 is CR8 or N; w is-NH-or-N = CH-; in the formula, R1 is-R < 9 >-COO < 10 >,-(CR < 122 >) < n >-R < 11 >-(CR < 122 >) < n >-O-H,-(CR < 122 >) < m >-O-H,-(CR < 122 >) < h >-COO < 10 > or-R < 11 >-CONR < 13 >-R < 14 >. The compound provided by the invention has strong inhibitory activity on influenza virus, and is subjected to in-vivo antiviral activity test, action mechanism analysis and pharmacokinetic characteristic evaluation at the same time.

An ink comprises (i) a carrier; (ii) graphene and / or graphene oxide particles dispersed in the carrier; and (iii) a viral active and / or anti-microbial component adhered to the graphene and / or graphene oxide particles.

This device for outputting a virus action suppressing component carries out: a step for detecting the humidity in a space when an active ingredient composed of a virus action suppressing component is outputted into the space; a step for determining whether the humidity in the space is at least a first set value; and a step, if the humidity in the space is at least the first set value, for increasing the amount of the active ingredient outputted into the space more than in the case where the humidity in the space is less than the first set value. This configuration makes it possible to increase the virus action suppressing effect when the humidity is high.

The invention discloses a heterocyclic compound shown as a formula (I) or a formula (IIa) or a stereoisomer and a medicinal salt thereof, and a pharmaceutical composition containing the formula (I) or the formula (IIa). The compound disclosed by the invention has remarkable anti-HSV virus activity and physicochemical properties of a long-acting compound, and can be used for preparing a drug of a virus HSV inhibitor or a pharmaceutical composition containing the drug and the like.

The invention discloses a nucleoside compound and application thereof, and mainly relates to a nucleoside compound as shown in a formula (I) or various prodrugs, stereoisomers, pharmaceutically acceptable salts and racemic compounds of the nucleoside compound, a pharmaceutical composition containing the formula (I) and application of the nucleoside compound or the prodrugs, the stereoisomers, the pharmaceutically acceptable salts and the racemic compounds in preparation of drugs for preventing and / or treating RNA virus infection. Furthermore, the compound disclosed by the invention has remarkable broad-spectrum anti-RNA virus activity, overcomes the instability of a raw medicine in water, has a good patent medicine prospect and good oral bioavailability, and can be used for preparing a medicine of a virus RNA dependent RNA polymerase inhibitor or a medicine composition containing the medicine and the like.

Described herein are compositions, uses thereof, and methods for treating a viral infection in a host cell or organism infected by the virus, such as coronaviruses, Zika virus, Lassa virus, Crimean Congo hemorrhagic fever virus, hepatitis E virus, and other RNA viruses. Also described herein are synthetic rocaglate compositions, uses thereof, and methods for reducing or inhibiting translation initiation of a messenger ribonucleic acid (mRNA) of a virus in a host cell or organism infected by the virus.

The invention relates to the technical field of biological medicine, in particular to application of geldanamycin in preparation of a medicine for preventing and treating Newcastle disease virus. The compound with antifungal activity is obtained by separating, purifying and identifying the active substances of the strain, and is further verified to be geldanamycin. Through intracellular and extracellular combined experiment verification, the specific antiviral activity of the drug geldanamycin on the Newcastle disease virus is defined, and the geldanamycin can inhibit protein expression of the Newcastle disease virus, inhibit virions from being adsorbed to cells and directly inactivate the Newcastle disease virions; meanwhile, the geldanamycin can also up-regulate expression of an antiviral interferon gene in a cell, so that an all-around antiviral effect is realized.

The invention discloses an application of an eIF2alpha kinase regulator in preparation of an anti-human coronavirus drug. Specifically, the compound provided by the invention has the activity of resisting human coronavirus HCoV-OC43 and / or resisting new coronavirus of human coronavirus. The invention focuses on antiviral host factors, provides a target compound for targeting host eIF2alpha kinase, eIF2alpha phosphorylation and protein synthesis, plays an antiviral role by accurately regulating and controlling host virus interaction, and is beneficial to overcoming virus resistance and obtaining broad-spectrum antiviral activity.

The invention relates to the technical field of medicines, and particularly discloses application of interferon alpha combined with stiripentanol in virus infection resistance. As an antiviral drug, interferon alpha has the problems of limited curative effect, remarkable side effect, narrow applicable crowd, inconvenience in medication and the like clinically. The invention finds that the accumulation of host lactic acid in the later stage of virus infection is a key negative factor, and lactic acid directly inhibits the antiviral activity of interferon alpha and induces inflammatory storm. Through combined use of a lactic dehydrogenase inhibitor stiripentol (Stiripentol, STP), lactic acid production is reduced, a lactic acid-mediated antiviral inhibition-inflammation promotion effect is reversed, and the antiviral activity of interferon alpha is enhanced and side effects are reduced. Experiments prove that the combined therapy can effectively inhibit virus replication and inflammatory factor expression, and a new strategy is provided for broad-spectrum antiviral therapy.

The invention discloses lactobacillus mucosa with porcine virus resisting activity and application of the lactobacillus mucosa, and relates to the technical field of microorganism application and virus prevention and control. It is found for the first time that the lactobacillus mucosa has broad-spectrum antiviral activity, not only has a remarkable inhibition effect on porcine reproductive and respiratory syndrome virus type 2 (PRRSV2) strains, but also can further resist porcine epidemic diarrhea virus (PEDV) and porcine rotavirus (PoRV); according to the present invention, the Lactobacillus mucosa is adopted to culture the supernatant, such that the supernatant does not have toxicity on Marc-145 cells; according to the PRRSV2 strain treated by using the supernatant, the expression level of virus RNA and protein and the filial generation virus titer are remarkably reduced, so that the infection ability is weakened; the culture supernatant directly acts with virus particles to block infection and replication of the virus particles; the product disclosed by the invention is derived from natural probiotics, is high in safety, environment-friendly and not easy to resist drugs, can be used for preparing a broad-spectrum anti-porcine virus biological preparation, provides a new strategy for preventing and controlling porcine virus diseases, and has a good industrial application prospect.

The present application relates to the technical field of biological medicine, in particular to a preparation method of varicella attenuated live vaccine, a freeze-drying protective agent and application thereof, which comprises the steps of cell culture, virus infection, complex enzymatic dissociation, protective ultrasonic disruption, clarification and collection, etc. The complex enzymatic dissociation adopts EDTA and recombinant trypsin combination to loosen the cells at low temperature; the protective ultrasonic disruption adopts a buffer solution containing trehalose and recombinant human blood albumin to resuspend the cells and perform intermittent ultrasonic disruption. The present application further provides a freeze-drying protective agent which is composed of trehalose, sorbitol, L-arginine, L-histidine and polyvinylpyrrolidone. The virus harvesting efficiency of the method is high, and the virus activity loss is small; the freeze-drying protective agent has good safety and excellent stability.

This invention relates to the application of salicylamide derivatives in the preparation of anti-small RNA virus drugs, belonging to the field of antiviral drug technology. This invention discloses the application of salicylamide and / or its derivatives in the preparation of anti-small RNA virus drugs. Through various experimental methods, this invention confirms that niclosamide and its derivatives HJW1107 and CZY1111 can significantly inhibit the early infection and replication of small RNA viruses such as EMCV, EV-D68, and CVA10, inhibit virus-induced cytopathic effects, and enhance the survival rate of infected cells. This indicates that niclosamide and its derivatives HJW1107 and CZY1111 have broad-spectrum antiviral activity and can be used to prepare therapeutic drugs against small RNA virus infections, thereby preventing and treating diseases caused by small RNA viruses, and has good clinical application prospects.

The invention provides a microtubule inhibitor with antiviral activity and application of the microtubule inhibitor, and belongs to the field of biological medicine. The microtubule inhibitor is a compound as shown in a formula I, a salt or a stereoisomer thereof. A microtubule inhibitor small molecule compound of a colchicine binding site is found through research, and the microtubule inhibitor small molecule compound has an excellent inhibition effect on microtubule polymerization and is even superior to colchicine. It is found through research that the compound has excellent antiviral activity on various coronaviruses, and especially the compound W66 has excellent antiviral activity. The invention provides more candidate compounds for antiviral microtubule inhibitors, and has a good application prospect. Formula I.

The invention provides a polypeptide ligand functionalized chiral zinc oxide nanoneedle, a preparation method thereof and application of the polypeptide ligand functionalized chiral zinc oxide nanoneedle in virus targeting and photocatalytic virus killing. The surface of the chiral zinc oxide nanoneedle is loaded with a polypeptide targeting ligand, and the polypeptide targeting ligand and the chiral zinc oxide nanoneedle are connected through a Zn-S covalent bond and an electrostatic adsorption effect. The invention provides a chiral zinc oxide nanoneedle material with a targeted virus killing effect. The preparation method comprises a chiral zinc oxide nanoneedle preparation step and polypeptide targeted ligand functionalization. The chiral zinc oxide nanoneedle obtained by the invention is a virus killing agent with virus killing activity under sunlight. The chiral engineering nanomaterial is a reliable platform for developing a photoresponse antiviral agent aiming at a conservative fusion mechanism, and the resistance to virus variation can be enhanced. The chiral zinc oxide nanometre with the targeted virus killing effect, provided by the invention, has important significance for coping with and complementing current protective equipment.

The present invention relates to a use of an anthocyanin-anionic polysaccharide complex for preventing or treating influenza virus A infection and, more specifically, to a pharmaceutical composition, a food / health functional food / health aid food composition, and a quasi-drug composition, each comprising an anthocyanin-anionic polysaccharide complex as an active ingredient for preventing or treating influenza virus A infection diseases. A composition comprising an anthocyanin-anionic polysaccharide complex as an active ingredient provided in the present invention exhibits excellent anti-viral activity against influenza virus A and as such, can find very advantageous applications in developing an agent for prevention or treatment of diseases caused by influenza virus A infection.

The application discloses an antibacterial and antiviral polypeptide Litomusin for white shrimp 81‑100 and application thereof, the molecular formula of the polypeptide is C 106 H 183 N 35 O 25 S1, and the amino acid sequence of the polypeptide is shown as SEQ ID NO. 01. The polypeptide has good water solubility, has significant antibacterial activity on various bacteria and fungi, has good antibacterial effect and high efficiency, has a wide antibacterial spectrum, has strong activity on white spot syndrome virus, has no toxicity on hematopoietic tissue (Hpt) cells of Procambarus clarkii, and has a good application prospect in drug research and development.

The application discloses a kind of based on CLDN1 protein's derivative peptide, fusion protein and its application, the derivative peptide includes the amino acid sequence as shown in SEQ ID NO:3, the amino acid sequence of the fusion protein is as shown in SEQ ID NO:2.The application finds that several derivative peptides containing CLDN1 protein extracellular loop EL1 peptide segment have significant inhibitory effect on various RNA and DNA envelope viruses.The fusion protein shows significant in vivo antiviral activity, can alleviate lung inflammation caused by RSV infection, and reduce viral nucleic acid level.Therefore, the derivative peptide and fusion protein based on CLDN1 protein designed in the application can be used for antiviral therapy or prophylactic drug research and development, and have wide application prospect.

This invention belongs to the field of biomedicine, specifically relating to the application of stilbene extract (SEP) in the preparation of antiviral active ingredients against porcine viruses. This invention extracts SEP from peony seeds or pod shells, which significantly inhibits the replication of porcine PRV virus in porcine kidney PK15 cells. Its effective concentration is 0.0078-5 μg / mL, the cellular half-lethal dose is 15.81 μg / mL, and the half-inhibitory dose against porcine PRV virus is 0.164 μg / mL; furthermore, 0.625 μg / mL SEP resulted in a cell viability of 84.7% and a virus inhibition rate of 90.4%. SEP exhibits better antiviral efficacy, a lower effective dose, and a higher safety dose against porcine viruses than resveratrol, paclitaxel, or a mixture of resveratrol and paclitaxel, showing promising application prospects in the development of feed, veterinary drugs, and pharmaceuticals for combating porcine viruses.

The invention relates to application of a compound 101-mer in preparation of an influenza vaccine adjuvant and an influenza vaccine, and belongs to the technical field of biology. The compound 101-mer is used as an influenza vaccine adjuvant for preparing an influenza vaccine, the immune protection effect of the influenza vaccine can be improved, the specific total IgG antibody titer of an influenza antigen and IgG1, IgG2a, IgG2b and IgG3 subtype antibody levels are improved, complete protection is provided after challenge, tissue damage is relieved, and the antiviral activity is remarkably superior to that of compounds 18-mer, 19-mer, 27-mer and LPS; as an adjuvant, the compound 101-mer does not have observable toxicity, can still be well tolerated under a high dosage, and has relatively high safety, and the safety of the compound 101-mer is remarkably superior to that of LPS (Lipopolysaccharide); the action mechanism is clear, and the compound can be used as a Dectin-2 agonist to activate a host immune system through a Syk / NF-kappa B signal channel.

This invention discloses an antimicrobial peptide, Cih1, and its applications. The amino acid sequence of antimicrobial peptide Cih1 is shown in SEQ ID NO.1. The antimicrobial peptide Cih1 provided by this invention is a cationic peptide, rich in cysteine ​​(-cys) residues, which can form an amphiphilic β-sheet secondary structure. This structure endows it with excellent antibacterial and antiviral activity, and can effectively inhibit the proliferation and invasion of pathogens in aquaculture water. Based on the broad-spectrum resistance of antimicrobial peptide Cih1 to pathogens, it can help aquatic animal hosts resist infection by various pathogens, and has broad application prospects in the field of anti-infective drug development for aquaculture.

The invention relates to a coronavirus inhibitor, in particular to a COVID-19 virus inhibitor, a pharmaceutical composition containing the inhibitor, and application of the medicine in the aspect of treating or preventing COVID-19 infectious diseases.

Human herpesviruses can infect barrier and immune cells of the intestinal tract to cause microbiome dysbiosis and inflammation. Microbiome dysbiosis can affect the availability of nutrients required for normal brain function. Inflammation can compromise the intestinal barrier and lead to microbial translocation. Microbial translocation can cause brain infection or a mimicry auto-immune response. The embodiments restrict herpesvirus activity and injury by 1) the oral administration of exosomes containing factors to inhibit viral activity and restore homeostasis, and 2) the oral administration of recombinant bacteria that produce exosomes containing factors to inhibit viral activity and restore homeostasis. Another embodiment is the treatment of alpha-HHVs mediated intestinal dysfunction by nucleoside analogs, such as famciclovir, which may be combined with anti-viral exosome therapy.

This invention relates to a method for promoting the antiviral activity of NK cells in vitro, specifically involving the steps of contacting NK cells with NUCB2 protein or mRNA or expression vector expressing the NUCB2 protein, thereby enhancing the antiviral activity of the NK cells.

The invention discloses a Peniterpheyl A derivative and application thereof in preparation of a new coronavirus resisting medicine. The fact that the Peniterpheyl A derivative has good new coronavirus resisting activity and low toxicity to normal cells is found for the first time. The chemical structure is shown in the specification.